Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : LastShadow's Position Trading -- Ignore unavailable to you. Want to Upgrade?

To: LastShadow who wrote (178)	9/3/1998 9:34:00 AM
From: Wallace Rivers	Respond to of 43080

FWIW, and for those with kids who download everything, I was sent a notice from a friend to NOT download a screensaver with the Budweiser Frog...it has a virus in it.

To: LastShadow who wrote (178)	9/3/1998 9:50:00 AM
From: R Hamilton	Read Replies (1) \| Respond to of 43080

GNE..they got fda panel approval yesterday....joe k on cnbc talked about genentech yesterday along with zeneca(ZEN), but by close, there was no news on the fda approval. as long as the stock mkt doesn't crash, it should so well today. US FDA panel backs Genentech's breast cancer drug BETHESDA, Md., Sept 2 (Reuters) - A unique biotech drug to combat advanced breast cancer was recommended for approval Wednesday by federal advisers. The drug, Genentech (GNE - news) Inc's Herceptin, targets the process that causes breast cancer by blocking the action of the HER2/neu gene, thus helping to keep tumors from growing. A panel of advisers to the U.S. Food and Drug Administration said the therapy provided clinical benefits for many of the 25-30 percent of women with breast cancer who have HER2 tumors. They said the drug could be approved for use alone or in combination with other chemotherapies, but only after women had failed to improve on at least one other chemotherapy drug. They said it should not be used with Anthracycline-type chemotherapy drugs because of the potential for dangerous cardiac side effects The FDA is not bound by its advisory panel's recommendations, but usually follows them. More Quotes and News: Genentech Inc (NYSE:GNE - news) Related News Categories: health good luck, rhonda GNE +1